Insulet (PODD) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is PODD's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Fifth Third Bancorp boosted its stake in Insulet Corporation (NASDAQ: PODD) by 21.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owne…

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

After reaching an important support level, Insulet (PODD) could be a good stock pick from a technical perspective. PODD surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.…

Insulet is undervalued, trading at a sub-median multiple despite 20% revenue growth and expanding margins. PODD's pharmacy-based, fully disposable model and dominant new patient onboarding differentiate it from emerging …

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.…

ACTON, Mass.--(BUSINESS WIRE)--In recognition of World Diabetes Day on November 14, 2026, Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipo…

Chicago Partners Investment Group LLC increased its holdings in shares of Insulet Corporation (NASDAQ: PODD) by 48.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 13,883 shares o…

Insulet NASDAQ: PODD reported third-quarter revenue of $842 million, up 19.2% on a reported basis and 19.6% on a constant-currency basis, as international growth outpaced the company's plans and U.S. performance landed w…

Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript…

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street es…

Insulet (PODD) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.24 per share a year ago.…

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results…

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 2026 Jeffe…

International Assets Investment Management LLC grew its position in Insulet Corporation (NASDAQ: PODD) by 61,543.8% during a recent quarter, according to the company in its most recent disclosure with the Securities and …

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program…

Curated Wealth Partners LLC lessened its holdings in shares of Insulet Corporation (NASDAQ: PODD) by 83.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commiss…

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discov…

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financ…

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Insulet (NASDAQ: PODD) Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while …

Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript…

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insi…

NEW YORK--(BUSINESS WIRE)---- $PODD #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) an…

New York, New York--(Newsfile Corp. - August 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26…

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ: …
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

